[{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Chiesi Group"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Chiesi Group"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Episalvan","moa":"Transient potential channel receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Lomitapide","moa":"MTP","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Medison Pharma"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"IRELAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lomitapide","moa":"MTP","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Amryt Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
